New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 29, 2012
08:15 EDTTKMRTekmira Pharmaceuticals acquires worldwide license to novel RNAi Technology
Tekmira Pharmaceuticals announced that it has obtained a worldwide, non-exclusive license to a novel RNAi payload technology called Unlocked Nucleobase Analog, or UNA, from Marina Biotech, for the development of RNAi therapeutics. UNA technology can be used in the development of RNAi therapeutics, which treat disease by silencing specific disease causing genes. UNAs can be incorporated into RNAi drugs and have the potential to improve them by increasing their stability and reducing off-target effects.
News For TKMR From The Last 14 Days
Check below for free stories on TKMR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2014
18:38 EDTTKMROn The Fly: After Hours Movers
Subscribe for More Information
17:49 EDTTKMRGSK, Shire rumored to be interested in Tekmira, Daily Mail says
GlaxoSmithKline (GSK) and Shire (SHPG) are rumored to be interested in a bid for Tekmira (TKMR), reports Daily Mail. Tekmira could be a value to potential suitors, capitalized at approximately GBP 400M and the company could cost over GBP 1B in a takeover, Daily Mail adds. Reference Link
August 20, 2014
14:11 EDTTKMRTekmira lipid nanoparticle targeting Marburg virus highlighted in journal
Subscribe for More Information
August 18, 2014
10:01 EDTTKMROn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:46 EDTTKMRTekmira initiated with an Outperform at Leerink
Subscribe for More Information
August 13, 2014
17:23 EDTTKMRTekmira breaks regular session low in extended trading
Shares were last down 9.4% to $16.84 in after hours trading. Next support is at $15.87. Resistance is at $17.30, the regular session's low of the day.
17:09 EDTTKMRTekmira down 7% following Q2 results, corporate update
17:04 EDTTKMRTekmira slips in extended session trade, levels to watch
Subscribe for More Information
16:40 EDTTKMRTekmira to resume trading at 5:00pm ET
Subscribe for More Information
16:38 EDTTKMRTekmira sees filing IND, Equiv for TKM-HBV in 2H14
The company said the following: "The single ascending dose portion of the TKM-Ebola Phase I clinical trial has been successfully completed in healthy human volunteers. As per the protocol maximum tolerated dose was established to be 0.3 mg/kg for healthy subjects without steroid premedication. In July, we received notice from the U.S. Food & Drug Administration that our TKM-Ebola program was on clinical hold. Subsequently, the company received written notice from the FDA modifying the clinical hold to a "partial clinical hold," allowing for the potential use of TKM-Ebola in individuals who have a confirmed or suspected Ebola infection. The company remains on clinical hold as it relates to the multiple-ascending dose portion of the Phase I clinical study in healthy volunteers with TKM-Ebola. The company expects this matter to be resolved by Q4 2014. Our therapeutic, TKM-Ebola, is currently an unapproved agent and the regulatory framework to support its use in Africa has not yet been established. Given the severity of the situation, we are carefully evaluating options for use of our investigational drug within accepted clinical and regulatory protocols. This includes discussions with government agencies and NGO's, including the WHO, in various countries on the potential use of TKM-Ebola to treat Ebola virus infected individuals. There can be no assurance that an appropriate framework for the use of this product will be found. We will continue to provide updates as necessary when clinical and regulatory pathways become confirmed. Within our TKM-PLK1 clinical trial targeting GI-NET and ACC patients, we saw an additional RECIST qualifying Partial Response, defined as a greater than 30 percent reduction in target tumor lesions. This patient is continuing on therapy and has achieved a 44 percent reduction in their target tumor mass, located outside of the liver. Furthermore, scans of the target tumor lesions demonstrate signs of necrosis, indicative of anti-tumor activity. We have initiated a Phase I/II clinical study of TKM-PLK1 in patients with Hepatocellular Carcinoma. We intend to file an Investigational New Drug application, or equivalent, in the second half of 2014, in order to advance our TKM-HBV program into a Phase I clinical study, with initial data available in 2015."
16:34 EDTTKMRTekmira provides operational update
Subscribe for More Information
16:33 EDTTKMRTekmira reports Q2 EPS (28c), consensus (26c)
Reports Q2 revenue $1.8M, consensus $3.69M.
16:25 EDTTKMRTekmira trading halted, pending news
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use